Dermata Therapeutics Inc (DRMA)vsRevolution Medicines Inc (RVMD)
DRMA
Dermata Therapeutics Inc
$1.34
0.00%
HEALTHCARE · Cap: $5.21M
RVMD
Revolution Medicines Inc
$186.88
-2.22%
HEALTHCARE · Cap: $40.39B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. DRMA earns a higher WallStSmart Score of 26/100 (F).
DRMA
Avoid26
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
DRMA is growing revenue faster at 0.0% — sustainability is the question.
DRMA generates stronger free cash flow (-2M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DRMA scores higher overall (26/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company dedicated to innovating treatments for dermatological conditions, with a primary focus on its lead candidate, DMT310. Employing a proprietary delivery system, DMT310 aims to enhance the effectiveness of acne therapies and address critical unmet needs in the dermatology sector. With a strategically developed pipeline and a commitment to pioneering solutions, Dermata is poised to significantly impact the skin health landscape and improve patient outcomes. As the company progresses through its clinical trials, it holds the potential to become a transformative force in the treatment of various skin disorders.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?